Market Overview

Musk Says He Ignored Analyst Questions Because They 'Represent A Short-Seller Thesis, Not Investors'

Musk Says He Ignored Analyst Questions Because They 'Represent A Short-Seller Thesis, Not Investors'
Related TSLA
Gordon Johnson: With 90-95% Conviction Rate, The DoJ's Tesla Investigation Is 'Concerning For All Those Long The Stock'
Stock Market Appears To Focus On US-China Tariff News As US, Canada Continue Talks
Ferrari: Expensive Or Not? (Seeking Alpha)

Tesla Inc (NASDAQ: TSLA)’s CEO can drive the stock with his enthusiasm and crush it with his ennui.

After catalyzing an 8-percent slide with dismissive remarks about Tesla’s earnings and strategy, Elon Musk defended his posture Friday.

In a series of tweets, Musk initiated a “tedious discussion about Tesla stock” where he delineated circumstances around Wednesday’s conference call.

“First, it’s important to know that Tesla is the most shorted (meaning most bet against) stock on the market & has been for a while,” he tweeted. “[...] The 2 questioners I ignored on the Q1 call are sell-side analysts who represent a short seller thesis, not investors.”

Musk reflected on two interactions that drew particular criticism.

Bernstein analyst Toni Sacconaghi Jr. was told “boring, bonehead questions are not cool” after inquiring about capital requirements, and a Model 3 reservation question from RBC’s Joseph Spak prompted a sharp and sustained shift from analyst queries to those of a retail investor.

One tweeter pushed back on the Model 3 position and requested indications for sustainable demand.

Tesla's stock closed Thursday at $284.45 per share.

Related Links:

Tesla's Q1 Earnings Recap: Per-Share Loss Better Than Expected, Model 3 Updates

With Consumer Happiness Dropping, Is Tesla In Real Trouble?

Posted-In: Elon Musk Model 3 RBC Capital Markets Toni Sacconaghi Jr.Analyst Color News Top Stories Best of Benzinga


Related Articles (TSLA)

View Comments and Join the Discussion!

The Market In 5 Minutes: Buffett-Apple, Activision Blizzard, Weight Watchers And More

Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down